Hormone levels following surgical and medical castration: defining optimal androgen suppression

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2018,（4）
• 页码范围: 405-406
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/aja.aja_38_17

摘要

Dear Editor, In the 1940s,Charles Huggins discovered that surgical castration produced remarkable palliative benefits for men with advanced prostate cancer,an effect we now understand to be mediated through depriving the androgen receptor (AR) from its ligands (i.e.,testicular-derived androgens).In the years since,medical forms of androgen deprivation therapy (ADT) have largely replaced orchiectomy as the predominate means of achieving castrate testosterone (T) levels,and currently,luteinizing hormone-releasing hormone (LHRH) agonists (e.g.,leuprolide) are the most common form of ADT.Importantly,studies have shown that LHRH agonists are clinically efficacious and,similar to surgical castration,drive T below 50 ng d1-1 for most patients.1